GILD - ギリアド・サイエンシズ (Gilead Sciences Inc.) ギリアド・サイエンシズ

 GILDのチャート


 GILDの企業情報

symbol GILD
会社名 Gilead Sciences Inc (ギリアド・サイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ギリアド・サイエンシズ(Gilead Sciences Inc.)は医薬品の発見・開発・商業化を行う研究型バイオ医薬品会社である。同社の製品ポートフォリオと治験薬のパイプラインはヒト免疫不全ウイルス、後天性免疫不全症候群(HIV/AIDS)、肝疾患、癌、炎症、呼吸器疾患、心血管疾患を含む。HIV/AIDS患者用製品は「Descovy」、「Odefsey」、「Genvoya」、「Stribild」、「Complera」、「Eviplera」、「Truvada」、「Emtriva」、「Tybost」、「Vitekta」を含む。肝臓疾患患者用製品は「Vemlidy」、「Epclusa」、「Harvoni」、「Sovaldi」、「Viread」、「Hepsera」を含む。同社は血液学・腫瘍疾患の患者にZydeligを提供する。心臓血管疾患の患者用製品は「Letairis」、「Ranexa」、「Lexiscan」を含む。炎症・呼吸器疾患治療用の製品は「Cayston」と「Tamiflu」を含む。   ギリアド・サイエンシズは米国の医薬品会社。主要製品は抗HIV薬の「ツルバダ」、「アトリプラ」、B型肝炎治療薬「ヘプセラ」、「ビリア―ド」、侵襲性真菌感染症治療薬「アンビゾ―ム」、肺動脈高血圧症治療薬「レタイリス」、サイトメガロウイルス性網膜炎治療薬「ビスタイド」、慢性狭心症治療薬「ラネクサ」など。本社はカリフォルニア州。   Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.
本社所在地 333 Lakeside Drive Foster City CA 94404 USA
代表者氏名 John C. Martin ジョンC.マーティン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 650-574-3000
設立年月日 31929
市場名 NASDAQ National Market System
ipoyear 1992年
従業員数 10000人
url www.gilead.com
nasdaq_url https://www.nasdaq.com/symbol/gild
adr_tso
EBITDA EBITDA(百万ドル) 11943
終値(lastsale) 76.4
時価総額(marketcap) 99040421305.2
時価総額 時価総額(百万ドル) 94982.88
売上高 売上高(百万ドル) 23197
企業価値(EV) 企業価値(EV)(百万ドル) 98125.88
当期純利益 当期純利益(百万ドル) 7690
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Gilead Sciences Inc. revenues decreased 21% to $10.74B. Net income before extraordinary items decreased 42% to $3.35B. Revenues reflect Antiviral products segment decrease of 26% to $9.14B. Net income also reflects Research and development expenses increase of 19% to $2.13B (expense) Selling general and administrative expe increase of 13% to $1.98B (expense).

 GILDのテクニカル分析


 GILDのニュース

   Steroids can seriously reduce risk of death from COVID-19, new trials show. The WHO is strongly recommending them.  2020/09/04 16:13:00 Business Insider
Summary List Placement Corticosteroids — a cheap and widely available class of drugs — can help people with serious cases of COVID-19 survive, according to trial results published this week. A robust analysis looking at seven trials of corticosteroids found that when patients on ventilators were treated with steroids, they had a 30% chance of dying, compared with a 38% chance among patients who didn't take steroids. For patients treated without ventilators, the benefit was even greater: People given steroids had a 23% chance of dying, compared with a 42% chance for people in a control group. "This is equivalent to around 68% of [the sickest] patients surviving after treatment with corticosteroids, compared to around 60% surviving in the absence of corticosteroids," the researchers said, according to Reuters . The steroids in the trials included methylprednisolone, hydrocortisone and dexamethasone. Based on the results, the World Health Organization issued a "strong recommendation" on Wednesday that doctors give seriously ill COVID-19 patients dexamethasone or hydrocortisone.
   Gilead files supplemental U.S. application for expanded use of Yescarta (NASDAQ:GILD)  2020/09/04 12:54:54 Seeking Alpha
Gilead Sciences (NASDAQ:GILD) unit Kite has filed a supplemental marketing application to the FDA seeking approval of Yescarta (axicabtagene ciloleucel) fo
   Remdesivir prices may rise after Gilead gets full authorisation from USFDA  2020/09/04 12:15:00 Business Standard
In August, Gilead filed an application with the US Food and Drug Administration (USFDA) seeking full approval for remdesivir (Veklury)
   Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates  2020/09/01 22:05:07 Benzinga
August was a disappointing month as far as regulatory decisions are concerned. The FDA turned down several applications, citing different reasons. Notable among the candidates that received the thumbs down were rheumatoid arthritis investigational therapy filgotinib sponsored by Gilead Sciences, Inc. (NASDAQ: GILD ) and BioMarin Pharmaceutical Inc.'s (NASDAQ: BMRN ) investigational gene therapy for hemophilia A. That said, the month saw approvals of eight new molecular entities, taking the total for the year to 38. Here are the key PDUFA dates scheduled for September. Bristol-Myers Squibb Awaits Nod For Blood Cancer Maintenance Therapy Company: Bristol-Myers Squibb Co's (NYSE: BMY ) Type of Application: NDA Candidate: CC-486 Indication: Acute myeloid leukemia Date: Aug. 3 CC-486 is an investigational oral hypomethylating agent, for the maintenance treatment of adult patients with acute myeloid leukemia, who achieved complete remission or complete remission with incomplete blood count recovery.
   Jounce inks license deal with Gilead valued up to $805M (NASDAQ:JNCE)  2020/09/01 12:47:35 Seeking Alpha
Jounce Therapeutics (NASDAQ:JNCE) enters into an agreement with Gilead Sciences (NASDAQ:GILD) under which the latter will have exclusive global rights to p
   Steroids can seriously reduce risk of death from COVID-19, new trials show. The WHO is strongly recommending them.  2020/09/04 16:13:00 Business Insider
Summary List Placement Corticosteroids — a cheap and widely available class of drugs — can help people with serious cases of COVID-19 survive, according to trial results published this week. A robust analysis looking at seven trials of corticosteroids found that when patients on ventilators were treated with steroids, they had a 30% chance of dying, compared with a 38% chance among patients who didn't take steroids. For patients treated without ventilators, the benefit was even greater: People given steroids had a 23% chance of dying, compared with a 42% chance for people in a control group. "This is equivalent to around 68% of [the sickest] patients surviving after treatment with corticosteroids, compared to around 60% surviving in the absence of corticosteroids," the researchers said, according to Reuters . The steroids in the trials included methylprednisolone, hydrocortisone and dexamethasone. Based on the results, the World Health Organization issued a "strong recommendation" on Wednesday that doctors give seriously ill COVID-19 patients dexamethasone or hydrocortisone.
   Gilead files supplemental U.S. application for expanded use of Yescarta (NASDAQ:GILD)  2020/09/04 12:54:54 Seeking Alpha
Gilead Sciences (NASDAQ:GILD) unit Kite has filed a supplemental marketing application to the FDA seeking approval of Yescarta (axicabtagene ciloleucel) fo
   Remdesivir prices may rise after Gilead gets full authorisation from USFDA  2020/09/04 12:15:00 Business Standard
In August, Gilead filed an application with the US Food and Drug Administration (USFDA) seeking full approval for remdesivir (Veklury)
   Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates  2020/09/01 22:05:07 Benzinga
August was a disappointing month as far as regulatory decisions are concerned. The FDA turned down several applications, citing different reasons. Notable among the candidates that received the thumbs down were rheumatoid arthritis investigational therapy filgotinib sponsored by Gilead Sciences, Inc. (NASDAQ: GILD ) and BioMarin Pharmaceutical Inc.'s (NASDAQ: BMRN ) investigational gene therapy for hemophilia A. That said, the month saw approvals of eight new molecular entities, taking the total for the year to 38. Here are the key PDUFA dates scheduled for September. Bristol-Myers Squibb Awaits Nod For Blood Cancer Maintenance Therapy Company: Bristol-Myers Squibb Co's (NYSE: BMY ) Type of Application: NDA Candidate: CC-486 Indication: Acute myeloid leukemia Date: Aug. 3 CC-486 is an investigational oral hypomethylating agent, for the maintenance treatment of adult patients with acute myeloid leukemia, who achieved complete remission or complete remission with incomplete blood count recovery.
   Jounce inks license deal with Gilead valued up to $805M (NASDAQ:JNCE)  2020/09/01 12:47:35 Seeking Alpha
Jounce Therapeutics (NASDAQ:JNCE) enters into an agreement with Gilead Sciences (NASDAQ:GILD) under which the latter will have exclusive global rights to p
   U.S. to ship remdesivir to states including California and Texas with rising COVID-19 cases  2020/06/26 18:28:19 Reuters
The U.S. government will ship more of Gilead Sciences Inc's antiviral treatment remdesivir to states experiencing an increase in COVID-19 cases including California, Texas, Florida and Arizona, according to the Department of Health and Human Services' website.
   Coronavirus : Est-il « simple comme chou » de vérifier les liens entre médecins et laboratoires pharmaceutiques, comme le dit Didier Raoult ?  2020/06/26 14:52:04 20 Minutes France
Lors de son audition à l’Assemblée nationale mercredi, Didier Raoult a accusé les opposants à la chloroquine de conflits d’intérêts avec Gilead Sciences
   EU drugs agency endorses Gilead's remdesivir as COVID-19 treatment  2020/06/26 13:48:27 New Europe
European Medicines Agency (EMA) recommended on Thursday granting a conditional marketing authorization (CMA) to Gilead’s antiviral drug called remdesivir, for the treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen. Remdesivir, is th
   Coreia do Sul endossa remdesivir para Covid-19 e sugere cautela com dexametasona  2020/06/26 12:48:00 Extra
Por Sangmi ChaSEUL (Reuters) - A Coreia do Sul acrescentou o tratamento antiviral remdesivir da Gilead Sciences às suas diretrizes de tratamento do coronavírus em sua primeira revisão de recomendações desde o início do… Leia mais
   COVID-19 treatment: Remdesivir now recommended by European regulator! Check details  2020/06/26 08:49:00 The Financial Express
The European Medicines Agency (EMA) has revealed that its human medicines committee (CHMP) recommended a conditional approval remdesivir produced by Gilead Sciences Inc for the treatment of the novel Coronavirus.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ギリアド・サイエンシズ GILD Gilead Sciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)